-
1 Comment
Acerus Pharmaceuticals Corporation is currently in a long term uptrend where the price is trading 8.5% above its 200 day moving average.
From a valuation standpoint, the stock is 96.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 39.4.
Acerus Pharmaceuticals Corporation's total revenue sank by 47.3% to $271K since the same quarter in the previous year.
Its net income has dropped by 82.9% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 13.0% to $-5M since the same quarter in the previous year.
Based on the above factors, Acerus Pharmaceuticals Corporation gets an overall score of 2/5.
Exchange | TO |
---|---|
CurrencyCode | CAD |
ISIN | CA00444G4051 |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Beta | 1.03 |
---|---|
Market Cap | 3M |
PE Ratio | None |
Target Price | 0.38 |
Dividend Yield | 0.0% |
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ASP.TO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025